ABSTRACT: Backgro und: Sexual dysfunction in women with Parkinson's disease is poorly understood and research in this area is scarce. The objectives of this study were sexual function characterization in female Parkinson's disease patients, description of sexual dysfunctions, correlation with disease characteristics, and comparison with matched healthy controls. Methods: Social and demographic data from consecutive female patients with Parkinson's disease and matched healthy controls were collected. The following instruments were used: UPDRS, the Hoehn and Yahr scale, the Beck Depression Inventory-II, the Female Sexual Function Index, and the Sexual Dysfunction Inventory. The only exclusion criterion was cognitive deterioration precluding comprehension of the study scope and its instruments. Results: Of the 95 patients identified, 61 were included. Mean age was 66 years (range 40-89 years), and mean disease duration was seven years (range 1-18 years). Twenty-nine presented an akinetic-rigid syndrome, 25 tremoric disease, and, the remaining, a mixed type of disease. Mean "on" total/part III UPDRS scores were 46 6 15.0 and 31 6 8.9. Sexual dysfunction was present in 86.9% of patients and 79.0% of controls, according to the Female Sexual Function Index (p < .01), and in 57.4% of patients and 22.6% of controls, according to the Sexual Dysfunction Inventory (p < .001). Multivariate binary logistic regression identified age and depressive symptoms as positive predictors in the severity of sexual dysfunction. Disease duration, UPDRS part III score, Hoehn and Yahr stage, and antiparkinsonian medication did not show significant predictive value. Conclusions: Sexual dysfunction is more prevalent in women with Parkinson's disease than in controls and is predicted by older age and severity of depressive symptoms. V C 2016 International Parkinson and Movement Disorder Society
of this issue. 10 In clinical practice, management of PD patients tends to be focused on motor symptoms, whereas sexual function is an issue rarely raised, both by neurologists and patients. 11, 12 There may be an erroneous assumption that PD patients, being generally middle-aged or elderly, are not concerned about sexual dysfunction. 5 Also, the subject of sexuality in older people remains a taboo in many cultures, particularly among women. 13 There is, indeed, a decline in sexual activity with aging.
14 However, despite this, among women who still have a partner and within the age classes of 65 to 74 and 75 to 85, there are about 40% and 17%, respectively, still sexually active. 15 Both men and women who rate their health as poor are less likely to be sexually active and report sexual problems more frequently. 14, 15 Nevertheless, sexual issues are seldom discussed with physicians, and women are less likely than men to do so. 14 Moreover, physician-patient communication concerning sexuality is generally poor. Reasons pointed out for this include the unwillingness of both patients and physicians to talk about the subject, sex and age differences between patients and their doctors, and social prejudices and stereotypes regarding women's and older people's sexuality. 11, 16 In line with the scarcity of attention given to sexuality and sexual dysfunction in the general female population, the investigation of sexual dysfunction in PD patients is limited to a few published studies, which generally do not present a standardized methodology and tend to include both male and female patients, ignoring sex differences in sexual functioning. [17] [18] [19] There is only one published article focusing specifically on women with PD, which included 27 patients, and concluded that female PD patients were more likely to be dissatisfied with their sexual life, when compared with age-and marital status-matched controls. In addition, they suffered more from a decrease in libido, vaginal tightness, and involuntary urination during intercourse. 20 Another study examined a group of 103 PD patients of both sexes, using separate questionnaire sets for each sex, concluding that depression and anxiety play important roles in sexual function of female PD patients. 21 Because our knowledge of sexual dysfunction in women with PD is so scarce, the approved measures for its treatment are virtually nonexistent. 22 The American Academy of Neurology published a guideline concerning nonmotor symptoms treatment, but the only recommendation for sexual dysfunction treatment is sildenafil for men with erectile dysfunction. 23 
Objectives
The objectives of this study were to provide a better understanding of sexual function in female PD patients and to establish predictive factors for sexual dysfunction.
Methods Study Design and Population
The local ethics committee approved the study. Written informed consent was obtained from all participants, and the principles outlined in the Declaration of Helsinki were followed. Female PD patients, diagnosed according to UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria, 24 were consecutively recruited from an outpatient movement disorders clinic by two physicians who were not involved in the management of their illness. Of 95 eligible patients, 12 were excluded because of cognitive deterioration precluding study comprehension, and 22 declined participation citing lack of time (n 5 12), lack of interest (n 5 9), or celibacy (n 5 1). Assessments were conducted on the same day following routine neurological consultation. Motor evaluation was performed by the consulting neurologist, who was unaware of the patients' participation. After the consultation, the study's objectives were explained and consent was obtained by a neurologist and a psychiatrist, who gathered the remaining data to maintain confidentiality and anonymity. The control group was recruited from the waiting room of an orthopedics outpatient clinic (n 5 62) and was matched to the subjects for social and demographic characteristics. They were either patients being followed for nondisabling hand or shoulder problems (n 5 11) or were otherwise healthy women accompanying relatives in the waiting room (n 5 51).
Measures
Social and demographic information was collected, including age, ethnic background, residency (rural or urban), educational level, religion, and marital status. Clinical variables, retrospectively obtained from clinical records, included age of onset, disease duration, disease subtype (akinetic-rigid, tremoric, or mixed), current antiparkinsonian medication, "on" total Unified Parkinson's Disease Rating Scale (UPDRS) score, 25 and Hoehn and Yahr (H&Y) stage. 26, 27 Comorbidities, other current medication and menopausal status were also obtained from patients and controls.
Instruments
Sexual function was characterized in patients and controls using two instruments: the Female Sexual Function Index (FSFI) and the Sexual Dysfunction Inventory (SDI). The FSFI is a brief multidimensional self-report questionnaire concerning female sexual function. It includes 19 questions, assessing six domains of female sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) pertaining to the previous month. Each answer is given between 0/1 and 5. Scores of individual items that comprise a domain are added, and the sum is multiplied by the domain factor. The sum of the six domain scores results in the full scale score, which ranges between 2 and 36, the latter meaning no sexual dysfunction, as increasing scores indicate better sexual function. 28 Although validated for the Portuguese population, no cutoff has yet been identified in this population. 29 Therefore, the original > 26.5 cutoff was used. 30 The female version of the SDI is a semistructured interview that specifically evaluates each of the sexual dysfunction dimensions included in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). 31 It also provides data regarding sexual orientation, current and past relationships, frequency of sexual behaviors (intercourse, outercourse, and masturbation), and past unwanted sexual experiences. 32 This instrument facilitates the assignment of consistent and valid clinical diagnoses, based on criteria defined by the DSM-IV. 31 As with the FSFI, this interview is translated into the Portuguese language. 33 Severity of depression was assessed, both in patients and controls, using the Beck Depression Inventory-II (BDI-II), which is a 21-question self-report questionnaire, comprising symptoms of depression (such as sadness), cognitions (such as guilt), and physical symptoms (such as fatigue). In this last category, a question is included (item 21) related to "loss of interest in sex." Every question has a set of at least four possible answers, ranging in intensity. Each is assigned a value from 0 to 3, and a total score is calculated through the sum of all individual values. 34, 35 For the Portuguese population, a score of 0 to 11 indicates minimal depression, 12 to 17 indicates mild depression, 18 to 23 indicates moderate depression, and 24 to 63 corresponds to severe depression. 36 
Statistical Analysis
Distribution normality was assessed through the Kolmogorov-Smirnov test. Independent-sample t, Mann-Whitney, chi-square, or Fisher tests were used to determine group differences in demographic and clinical variables, depending on the comparison and test assumption. Multivariate binary logistic regression was used to calculate predictive factors of sexual dysfunction in PD patients. The dependent variable was defined as sexual dysfunction, as determined by a FSFI total score less than 26.5. As covariates, we included clinical and demographic variables, either flagged as significant in the univariate group analysis or considered biologically meaningful. All statistical analyses were performed using SPSS, version 20 (IBM), with the statistical threshold for significance set at 0.05.
Results
As shown in Table 1 , mean age of the 61 female PD patients included was 66 years (range 40-89 years). The majority lived in rural areas (60.7%) and had an elementary education (75.4%). Most patients were married (67.3%). Mean age of the 62 controls was 63 years (range 35-84 years). The majority lived in rural areas (53.2%) and had an elementary education (61.3%). Most of them were married (72.6%). All subjects and controls were white, and the majority were Catholics.
Clinical characteristics are shown in Table 2 . Mean age at PD onset was 59 years, and mean disease duration was seven years. Patients were evenly distributed among different types of disease. All but one, having undergone deep brain stimulation, were currently taking dopaminergic medication. Most patients were in H&Y stage two or three H&Y stage 2 or 3 (n 5 53). Concerning comorbidities, 36 patients (59.0%) had a diagnosis of depression or were being treated at a psychiatric outpatient clinic because of depressive symptoms, whereas 28 (45.9%) were taking antidepressants, mostly selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors. Seven controls (11.3%) had also been diagnosed with major depression and were taking antidepressants (p < .001). Patients' mean BDI-II score was 8.5 6 7.2 (range 0-34). Sixteen patients (26.2%) presented a total score of at least 12, indicating the presence of mild to severe depressive symptoms. Regarding item 21 from the BDI-II, "loss of interest in sex," 27 patients (44.3%) answered they had not noticed any recent change in interest in sex, seven (11.5%) said they were less interested in sex than they used to be, five (8.2%) were much less interested in sex, and 22 (36.1%) had completely lost interest in sex. Therefore, 56% of our subjects reported less interest in sex on BDI-II. Control population mean BDI-II score was 6.2 6 4.0 (range 0-20), and six controls (9.7%) scored 12 or 
more, which indicated mild to moderate depressive symptoms. With respect to item 21, 47 controls (75.8%) claimed less interest in sex. Both severity of depressive symptoms and answers to item 21 did not significantly differ between patients and controls. Table 3 shows overall sexual function of patients and controls. All patients defined themselves as exclusively heterosexual, and most had a current partner (70.5%). At the time the study was conducted, according to SDI, the majority of PD patients did not have regular intercourse with their partner (60.7%). Of these, two (5.4%) had outercourse (or nonpenetrative sexual activities), and none practiced masturbation. All controls were exclusively heterosexual. Most had a current partner (77.4%). The majority had regular intercourse with the partner (64.5%). Of those who did not, eight (36.4%) had outercourse, and none practiced masturbation. Hence, PD patients were less likely to be sexually active, either regarding intercourse (p 5 .007) or outercourse (p 5 .001).
Sexual dysfunction assessment tools revealed the following: 52 patients (86.9%) had total scores less than 26.5 on the FSFI, indicating the presence of sexual dysfunction; 35 patients (57.4%) met diagnostic criteria for at least one type of sexual dysfunction, according to the SDI; and 20 (32.8%) met diagnostic criteria for more than one. Furthermore, the SDI identified the following subtypes of sexual dysfunction in PD patients (not mutually exclusive): hypoactive sexual desire disorder in 16 (26.2%), sexual aversion disorder in three (4.9%), sexual arousal disorder in 17 (27.9%), orgasmic disorder in 16 (26.2%), dyspareunia in 11 (18.0%), and vaginismus in one (1.6%). In turn, controls scored significantly higher in total FSFI (p < .01) and in individual domains of arousal (p 5 .041), orgasm (p 5 .018), and satisfaction 
Individual scores in desire, lubrication, and pain domains were not different from those of the patients. Forty-nine controls (79.0%) had a total FSFI score less than 26.5, which was not significantly different from PD patients (p 5 .482). Fourteen met diagnostic criteria for at least one type of sexual dysfunction in SDI (22.6%), and eight received a diagnosis of more than one dysfunction (12.9%). Therefore, according to the SDI, sexual dysfunction was significantly more prevalent in PD patients than in controls (p < .01). We have not found any case of hypersexuality. Group differences analysis of PD patients with and without sexual dysfunction (see Table 4 ) showed that patients with sexual dysfunction were significantly older, had higher UPDRS-II and BDI-II scores, and were more frequently taking antidepressants. Comparisons of patients with and without sexual dysfunction regarding other demographic (habitation area, educational level, marital status) and clinical variables did not show any significant differences.
We next looked to what degree demographic and clinical variables predicted the presence of sexual dysfunction in women with PD, as defined by the FSFI. Multivariate binary regression results showed that older age (OR, 1.14; 95% CI, 1.02-1.27: p < .05) and higher frequency of depressive symptoms (OR, 1.54; 95% CI, 1.03-2.29; p < .05) significantly predicted sexual dysfunction (see Table 5 ).
Discussion
Our results show that sexual dysfunction is highly prevalent in female PD patients and more frequent than in controls. To our knowledge, this is the first study approaching sexuality in female PD patients with different but complementary instruments, specifically developed to assess sexual function in women. Because of the lack of validated instruments for sexual function assessment in female PD patients, most 
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published studies used divergent methodologies, rendering comparison of results very difficult. In addition to being a female-specific instrument, the FSFI is brief and easy to apply, and offers the possibility of selfassessment, facilitating patient compliance and bypassing potential constraints related to this topic. Our study is further strengthened by the use of the female version of the SDI, a more detailed instrument, which provides a complementary qualitative approach to female sexual function. We decided to use both tests to suppress their individual liabilities. Alternative assessment instruments, namely, those used in previous studies, focus on both male and female aspects of sexuality and/or are not validated for the Portuguese population. 37, 38 As expected, the prevalence of sexual dysfunction found with each instrument was uneven, resulting in a difference of almost 30% in patients (87% with the FSFI, 57% with the SDI) and 60% in controls (79% with the FSFI, 23% with the SDI). Such discrepancy may be explained by the nature of each instrument. Given that with the SDI the identification of a sexual dysfunction rests on clinical criteria, the diagnosis is much stricter. To diagnose a particular dysfunction, according to the DSM-IV, the disturbance is required to cause marked distress or interpersonal difficulty. 31 In fact, it has been demonstrated in previous studies concerning the general female population that only a small proportion of sexually dysfunctional women report distress resulting from this issue. 39 Accordingly, some of the women we studied, patients and controls, who scored less than 26.5 on the FSFI, experienced no marked distress and could not have been formally diagnosed with a sexual dysfunction via the SDI. Moreover, if a woman, for any reason, has not had intercourse in the previous month, questions 3 to 14 and 17 to 19, which relate to arousal, lubrication, orgasm, and pain domains, will all have a score of 0 (no sexual activity or did not attempt intercourse). Hence, she will have a maximum of 12 on total FSFI, scoring for sexual dysfunction, 28 although she may not verbalize any signs of sexual dysfunction in a semistructured interview approach such as the SDI.
This may be the reason why, based on the FSFI cutoff, there were differences concerning current relationship status and monthly sexual activity between PD patients with and without sexual dysfunction (see Table 4 ).
The first published study evaluating female PD patients with a specific female sexuality questionnaire revealed a 36% prevalence of sexual dysfunction in 11 patients. 5 Kummer and colleagues also approached this issue by analyzing answers to item 21 of the BDI, and they found loss of libido in 65.6% of the 90 PD patients included (of both sexes), 18 which is comparable to our results. As in this study, we have demonstrated the predictive value of depression and older age in sexual dysfunction. In fact, age and depression have been identified as important predictors of sexual dysfunction in other previous studies. [19] [20] [21] 40 According to the SDI results, despite most PD patients having a partner, a large proportion were not sexually active, unlike controls of the same age and with the same menopausal and marital status. Although Patients sexual dysfunction was found to be independent of PD-related clinical variables (except UPDRS II score), the fact that matched controls were significantly more sexually active and had less sexual dysfunction points to a possible causal role of disease in sexual dysfunction. Previous studies have suggested higher UPDRS score 18 and H&Y stage 41 as relevant predictors of sexual dysfunction. The relation of sexual dysfunction to PD clinical variables may not have been shown in our analysis of differences in disease groups, probably, because there are too many variables for a relatively small cohort. It is also possible that age and depression are much more significant than other variables, as they are known to affect the sexual function of women in general 39, [42] [43] [44] [45] and with other chronic neurological diseases. [46] [47] [48] For instance, female multiple sclerosis patients also seem to have a high prevalence of sexual dysfunction (32% in a recent study of 85 subjects, also using the FSFI). 48 As in our study and others in PD patients, in multiple sclerosis patients, no correlations have been found between sexual dysfunction and disease duration, 
lesion burden, and disability, although a link between depression and sexual dysfunction in these patients has also been suggested. 49 In fact, a previous diagnosis of depression was meaningfully more frequent in female PD patients when compared with controls. However, the assessment of depressive symptoms through the BDI-II score did not significantly differ between groups. Furthermore, previous studies in depressed female patients revealed a lower prevalence of sexual dysfunctions compared with what we found in our cohort of PD patients -in 100,000 depressed women, 17.7% had hypoactive sexual desire disorder, 3.4% sexual aversion disorder, 5.8% sexual arousal disorder, and 7.7% orgasmic disorder. 50 Almost half of our patients were taking antidepressants, which is also an important aspect, given that some of these drugs, especially serotoninergic ones, may cause sexual side effects, such as decreased libido, arousal difficulties, delayed orgasm, and anorgasmia. 51 Still, only six patients had total BDI scores compatible with moderate to severe depressive symptoms (range 18-63), four of whom had a previous diagnosis of depression. We can argue that, although there was a high prevalence of depression and antidepressant medication in PD patients, their psychiatric disease was well managed, and, accordingly, most patients had a lower BDI score, in the mild depression range. Our study did not identify antidepressants as predictors of sexual dysfunction. However, when deciding to treat depression in PD patients, the potential of aggravating sexual dysfunction of several antidepressants must be taken into account. 51, 52 Whenever possible, nonpharmacological measures should be recommended to enable arousal, including sex counseling, 4 scheduling regular sexual activity, and exercise. 53, 54 The addition of bupropion may also play a beneficial role when antidepressant therapy is needed. 55 A prospective followup of this patients subgroup and an intervention aimed at reviewing the effects of changing to drugs with less sexual side effects could give us more information concerning the complex relation among PD, antidepressants, and sexuality. Regarding other physical comorbidities, we found a higher prevalence of vascular and gynecological diseases in controls than in patients. Considering these are known contributors to sexual dysfunction, 56 we would expect a higher prevalence of sexual dysfunction in controls. This appears to reinforce the major influence of depression in sexual dysfunction among female PD patients.
We believe our findings are of significant clinical relevance because sexual dysfunction has an important impact on patients quality of life. 57 
Limitations
Although our sample is larger than others previously studied, it may not be large enough to provide a complete identification of sexual dysfunction determinants in female PD patients.
We decided to exclude cognitively impaired patients, given the nature of the sexual dysfunction measures used. The inclusion of these patients would not guarantee reliable data, although it would possibly disclose different results.
Given that more than 50% of the total population only had an elementary education, it was necessary, in some, to apply the FSFI by direct interview. This may have induced some bias in the FSFI results.
There are other shortcomings related to the sexuality assessment instruments. As described above, the FSFI evaluates women with a current partner and with regular intercourse, only providing a superficial characterization of non-sexually active patients, who represent a substantial percentage of our sample. Not having had intercourse in the last month is sufficient to put the subject into the sexual dysfunction group. Another disadvantage of the FSFI is its exclusive reference to intercourse, ignoring other types of sexual activity (for example, oral or manual). Nevertheless, the SDI also entails certain disadvantages, being time consuming, on the one hand, and, given its openquestion format, possibly more prone to the emergence of constraints, on the other hand. Accordingly, we believe the FSFI is a good screening tool, whereas the SDI appears to be the best instrument to diagnose specific sexual dysfunctions. However, further studies using both the FSFI and the SDI in PD patients are needed, to allow us to fully confirm their validity in this population.
We did not find any case of hypersexuality in our sample, nor did we observe an increase in sexual fantasies accompanying disease progression, as was suggested in another study. 58 Nevertheless, the complaints related to hypersexuality are expressed by partners, not reported by patients. 4 , 59 As we did not interview partners, we cannot assure the entire validity of results regarding this issue. Moreover, many patients may feel heightened sexual drive and do not experience hypersexual behaviors, which is part of the impulse control disorder, 60 and this may not have been assessed with the instruments used.
Conclusions
Sexual dysfunction is more common in women with PD than in the general population, being predicted by older age and depression. It appears independent of PD-related clinical variables. Clinicians should systematically and thoroughly assess nonmotor symptoms in PD patients, keeping in mind that, when assessing possible sexual dysfunction, older and depressed female patients may be particularly vulnerable.
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